Nuvig Therapeutics Trigger: New CEO, New Pipeline
New Nuvig CEO David Woodhouse jumps in. Expect aggressive Phase 2 trial scale-up. Pitch CTMS & CDMO to boost commission and pipeline. Checklist for your next touch inside.
Published on
Do not index
Do not index
🚀 Battle Card: Nuvig Therapeutics, Inc.
Quick trigger:
👤 Decision Maker in the News
- David J. Woodhouse, Ph.D., Chief Executive Officer · 🔗 LinkedIn
💡 Why It Matters
- New leadership with deep finance, BD and biotech R&D chops signals an aggressive push through multiple Phase 2 trials and platform licensing. This Nuvig Therapeutics, Inc. sales trigger means they’ll be hunting partners to scale NVG-2089. → Source
🎯 Core Pain Point
- Scaling recombinant NVG-2089 production to meet complex Phase 2 & future commercial demand
- Securing strategic partnerships for broader BESTech™ platform indication rollout
💰 What to Pitch
- Primary: Clinical Trial Management Software → Accelerate Phase 2 enrollment, compliance & data insights
- Expansion: End-to-End Biologics CDMO Services → Ensure scalable, consistent NVG-2089 supply
🗺️ Quick Context
- HQ: Menlo Park, CA
- Employees: ≈ 75
- Rev: ≈ $10 M
- Website: nuvigtherapeutics.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Nuvig Therapeutics, Inc.’s business.
- Veeva Systems — CTMS / EDC
- Unique edge: Industry-specific Vault suite
- Evaluated by Dr. Woodhouse & VP Clinical Ops for seamless integration
- Medidata — CTMS / eCOA
- Unique edge: AI-driven trial analytics
- Evaluated by Head of Clinical for real-time insights
- Catalent — CDMO / Biologics
- Unique edge: End-to-end development to commercial supply
- Evaluated by CFO & Ops for scale reliability
✅ Do-Now Checklist
Connect with David J. Woodhouse on LinkedIn (link above)
Generate email + DM using the Copy-My-Prompt block (Step 7) referencing this Nuvig Therapeutics, Inc. sales trigger and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Capitalize on this Nuvig Therapeutics, Inc. sales trigger and get pipeline-driving intel daily.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑Clinical Trial Management Software❑
PROOF_METRIC = ❑≈ TBD❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = David
COMPANY = Nuvig Therapeutics, Inc.
DEPT = ≈ TBD
SIZE = 75
BOTTLENECK = Scaling recombinant NVG-2089 production
EVENT = CEO appointment
DETAIL = your CEO appointment
PAIN = scaling biologics manufacturing
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250909619704&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 75
REV_EST = ≈ 10 M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 75-person ≈ TBD
David—noticed your ≈ TBD team is ≈ 75.
That’s when Scaling recombinant NVG-2089 production slows growth.
We helped ≈ TBD fix this with Clinical Trial Management Software.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ ≈ TBD.
DM ≤45 words, TONE:
Saw your post about your CEO appointment — scaling biologics manufacturing.
Clinical Trial Management Software. ≈ TBD.
Quick chat?